Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Double Bond Pharmaceutical International AB's quarterly market cap
declined
from Sep. 2025 (kr24.79 Mil) to Dec. 2025 (kr24.48 Mil) but then
increased
from Dec. 2025 (kr24.48 Mil) to Mar. 2026 (kr25.62 Mil).
Double Bond Pharmaceutical International AB's annual market cap
declined
from Dec. 2023 (kr69.23 Mil) to Dec. 2024 (kr40.38 Mil) and
declined
from Dec. 2024 (kr40.38 Mil) to Dec. 2025 (kr24.48 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Double Bond Pharmaceutical International AB's Enterprise Value for Today is kr29.13 Mil.
Double Bond Pharmaceutical International AB (XSAT:DBP B) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Double Bond Pharmaceutical International AB Market Cap Related Terms
Double Bond Pharmaceutical International AB Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Double Bond Pharmaceutical International AB Market Cap Chart
Double Bond Pharmaceutical International AB Annual Data
XSAT:DBP B vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Double Bond Pharmaceutical International AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Double Bond Pharmaceutical International AB Market Cap vs Biotechnology Industry
Double Bond Pharmaceutical International AB Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Double Bond Pharmaceutical International AB (XSAT:DBP B) has a Market Cap of kr30.20 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Double Bond Pharmaceutical International AB and its competitors. According to the industry distribution chart, Double Bond Pharmaceutical International AB ranks #1330 out of 1423 companies in the Biotechnology industry, placing it in the top 93.5%.
Is Double Bond Pharmaceutical International AB's Market Cap too high?
Double Bond Pharmaceutical International AB's current Market Cap is kr30.20 Mil. Based on the distribution chart, Double Bond Pharmaceutical International AB ranks #1330 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Double Bond Pharmaceutical International AB has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Double Bond Pharmaceutical International AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Double Bond Pharmaceutical International AB ranks #1330 out of 1423 companies for Market Cap. This places Double Bond Pharmaceutical International AB in the lower half of its industry. The industry median Market Cap is 111.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.61, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Double Bond Pharmaceutical International AB and its competitors. For the Biotechnology industry, the median Market Cap is 111.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Double Bond Pharmaceutical International AB's current Market Cap is kr30.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Double Bond Pharmaceutical International AB stock overvalued right now?
Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB (XSAT:DBP B) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.06, compared to a current price of kr0.14 — trading 125.8% above its estimated fair value. The current Market Cap is kr30.20 Mil. Double Bond Pharmaceutical International AB's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Double Bond Pharmaceutical International AB (XSAT:DBP B), the current Market Cap is kr30.20 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Double Bond Pharmaceutical International AB (XSAT:DBP B) Overvalued in 2026?
Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB stock appears to be overvalued.
The current stock price of kr0.14 is trading 125.8% above its estimated GF Value™ of kr0.06.
GuruFocus considers Double Bond Pharmaceutical International AB to be Significantly Overvalued.
Key valuation signals for XSAT:DBP B:
Market Cap: kr30.20 Mil
GF Value™: kr0.06 vs. price of kr0.14 (125.8% above fair value)
No single metric tells the full story. See the XSAT:DBP B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Double Bond Pharmaceutical International AB Business Description
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.
30GF Score
Get the complete analysis for XSAT:DBP B
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:DBP B has been successfully added to your 
